Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Retained Earnings (2020 - 2025)

Historic Retained Earnings for Xeris Biopharma Holdings (XERS) over the last 6 years, with Q3 2025 value amounting to -$682.4 million.

  • Xeris Biopharma Holdings' Retained Earnings fell 234.75% to -$682.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$682.4 million, marking a year-over-year decrease of 234.75%. This contributed to the annual value of -$671.9 million for FY2024, which is 888.72% down from last year.
  • Latest data reveals that Xeris Biopharma Holdings reported Retained Earnings of -$682.4 million as of Q3 2025, which was down 234.75% from -$683.0 million recorded in Q2 2025.
  • In the past 5 years, Xeris Biopharma Holdings' Retained Earnings registered a high of -$409.3 million during Q3 2021, and its lowest value of -$683.0 million during Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' median Retained Earnings value was -$603.6 million (recorded in 2023), while the average stood at -$590.3 million.
  • Per our database at Business Quant, Xeris Biopharma Holdings' Retained Earnings tumbled by 3637.54% in 2021 and then plummeted by 234.75% in 2025.
  • Quarter analysis of 5 years shows Xeris Biopharma Holdings' Retained Earnings stood at -$460.1 million in 2021, then fell by 20.57% to -$554.8 million in 2022, then fell by 11.22% to -$617.0 million in 2023, then dropped by 8.89% to -$671.9 million in 2024, then decreased by 1.57% to -$682.4 million in 2025.
  • Its Retained Earnings was -$682.4 million in Q3 2025, compared to -$683.0 million in Q2 2025 and -$681.1 million in Q1 2025.